Home / Stocks / Wanbury Limited
WANBURY

Wanbury Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹181.66

Change

+7.28 (4.17%)

Open

₹173.2

Prev. Close

₹174.38

Day High

₹183.0

Day Low

₹170.25

Volume Analysis

Traded

278,889

Delivered

100,527

Delivery %

36.05%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (76.5%)
  • •Promoter holding is rising

Weaknesses (2)

  • •High debt-to-equity ratio (1.51)
  • •Below-average fundamentals quality score (42/100)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹199.1 ₹191.05 ₹186.35 ₹178.3 ₹173.6 ₹165.55 ₹160.85
Fibonacci ₹191.05 ₹186.18 ₹183.17 ₹178.3 ₹173.43 ₹170.42 ₹165.55
Camarilla ₹185.17 ₹184.0 ₹182.83 ₹178.3 ₹180.49 ₹179.32 ₹178.15

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-20.99%

1 Week

-9.14%

1 Month

-3.2%

3 Months

-31.41%

6 Months

-35.91%

1 Year

-21.1%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

21.83%

Net margin 5.17% × asset turnover 1.16x × equity multiplier 3.64x

Company Overview

Sector

Healthcare

Market Cap

₹676 Cr

P/E (TTM)

20.3

ROE

76.5%

Book Value

₹44.9

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Wanbury Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 42/100. The strongest factor is Business Quality (67/100), while Momentum (16/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (76.5%); promoter holding is rising; high debt-to-equity ratio (1.51); below-average fundamentals quality score (42/100). FII holding has been rising.

TopFund Score — Fundamentals Quality

42/100 — Weak

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

29

Growth

20

Valuation

64

Cash Flow

45

Corporate Governance

66

Momentum

16

Institutional Ownership

40

Business Quality

67

Risk & Volatility

22

Liquidity

27

From Screener.in

  • +Company has delivered good profit growth of 30.9% CAGR over last 5 years
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of 10.3% over past five years.
  • −Tax rate seems low

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Wanbury received ANVISA CADIFA approval for Metformin HCl EP grade; third consecutive API approval.

Wanbury reported Q2 FY27 revenue of Rs 182.9 crore and PAT of Rs 11.9 crore, plus approvals and launches.

Wanbury approved Q2 and H1 FY2027 results; formed Wanbury Skin Health subsidiary, commenced October 2026.

Tanuku plant received Australian TGA GMP certificate on 28 October 2026, valid until 9 December 2028.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2026
Sales + 124 126 133 146 144 146 139 131 161 133 172 163 183
Expenses + 118 119 119 133 127 124 121 120 141 120 142 139 160
Operating Profit 6 6 14 13 17 21 18 11 20 14 30 24 23
OPM % 4.52% 5.13% 10.64% 9.13% 12.0% 14.54% 13.03% 8.37% 12.41% 10.45% 17.23% 14.98% 12.43%
Other Income + 1 0 -3 1 1 1 26 1 2 1 2 0 0
Interest 4 7 8 6 8 8 7 8 10 10 9 8 6
Depreciation 3 3 3 3 3 3 3 3 3 3 3 4 4
Profit before tax -1 -3 1 5 7 10 34 1 8 1 19 14 12
Tax % 25.35% 7.54% -10.87% 6.0% -2.5% -0.19% 0.8% 0.0% 1.84% 5.38% -6.3% 0.88% 30.99%
Net Profit + -1 -3 1 5 7 10 34 1 8 1 20 13 9
EPS in Rs 0 -1 0 1 2 3 10 0 2 0 6 4 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 0 1 -1 25 17 16 5 -10 12 -8 23 24 —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Sep 2014 18m Mar 2015 6m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Sales + 661 250 420 432 370 391 367 392 511 485 557 600
Expenses + 637 228 387 414 438 375 344 374 475 459 484 520
Operating Profit 25 21 33 19 -68 16 23 18 36 26 73 80
OPM % 3.7% 9.0% 8.0% 4.3% -18.0% 4.1% 6.0% 4.7% 7.0% 5.0% 13.0% 13.0%
Other Income + -78 6 0 90 76 9 84 2 77 -3 26 0
Interest 48 19 32 36 31 40 33 23 21 21 29 37
Depreciation 23 5 9 10 10 10 10 10 11 12 13 13
Profit before tax -125 4 -7 62 -32 -25 65 -12 81 -10 56 30
Tax % 2.0% 28.0% 0.0% 1.0% -1.0% -1.0% 0.0% 2.0% 0.0% 1.0% 1.0% -3.0%
Net Profit + -128 3 -7 62 -32 -25 64 -13 81 -10 56 31
EPS in Rs -64 2 -4 27 -13 -10 26 -5 25 -3 17 9
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sales growth 44 — 68 3 -14 6 -6 7 30 -5 15 8

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2026
Reserves -212 -214 -209 -176 -208 -233 -168 -181 -56 -66 -5 26 122
Borrowings + 389 381 362 300 250 260 190 192 100 95 116 179 237
Other Liabilities + 209 209 215 265 207 236 232 253 276 241 199 176 178
Total Liabilities 406 396 388 412 273 286 279 289 353 304 343 414 572
Fixed Assets + 174 164 180 186 178 172 164 167 167 167 167 201 262
CWIP 13 19 14 10 10 9 14 11 2 2 3 5 17
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 219 213 193 216 84 105 101 111 183 135 174 208 292
Total Assets 406 396 388 412 273 286 279 289 353 304 343 414 572
Equity Capital 20 20 20 23 24 24 25 25 33 33 33 33 35

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Cash from Operating Activity + 68 40 43 43 32 30 44 17 41 20 4 26
Cash from Investing Activity + -6 -5 -20 -13 -1 -3 64 8 1 -9 -17 -51
Cash from Financing Activity + -71 -30 -28 -27 -33 -27 -108 -17 -29 -32 15 26
Net Cash Flow -9 5 -5 3 -2 0 0 7 13 -21 2 1
Free Cash Flow 56 35 22 29 30 25 36 12 42 7 -10 -23
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 278 188 129 234 -49 188 188 97 113 76 6 33

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 39.79% → 42.98%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 60.2% 60.02% 59.97% 59.21% 59.4% 58.68% 58.79% 56.08% 56.21% 56.39% 56.04% 56.28%
Promoters 39.79% 39.79% 39.79% 39.77% 39.76% 39.76% 39.63% 43.09% 43.08% 43.01% 43.01% 42.98%
FII 0.0% 0.18% 0.22% 1.02% 0.84% 1.55% 1.59% 0.82% 0.72% 0.59% 0.89% 0.71%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.06% 0.02%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Wanbury Limited (this stock) 676 20.3 4.3 76.5%
Rays Of Belief Limited 615 99.3 4.03 16.1%
Gaudium Ivf N Women H L 740 32.0 4.55 24.6%
Fabtech Technologies Ltd 609 20.5 1.39 12.0%
Zim Laboratories Limited 756 365.0 2.59 1.59%
Valiant Laboratories Ltd 570 35.2 1.72 -2.55%
Shree Ganesh Remedies Ltd 798 65.9 4.79 10.8%

Which Mutual Funds Hold Wanbury Limited?

Frequently Asked Questions about Wanbury Limited

Community Sentiment

What are other investors saying about Wanbury Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.